Delivery Order SPE2DR25D2012-SPE2DR26F1BWN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,852.15 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on December 2, 2025, with completion scheduled for December 3, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is an atypical antipsychotic medication used in...
- The Defense Logistics Agency awarded a delivery order valued at $4,171.92 to AmerisourceBergen Drug Corp for the supply of Rexulti 0.25 mg tablets (30-count) on November 10, 2025, with an ultimate completion date of November 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is an atypical antipsychotic medication used in...
- The Defense Logistics Agency awarded a $2,002.05 delivery order to AmerisourceBergen Drug Corp for Rexulti (brexpiprazole) 3 mg tablets in a 30-count package. This is a firm fixed price, competitively awarded order with no set-aside designation, with an ultimate completion date of December 30, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $7,143.68 to AmerisourceBergen Drug Corp for the supply of Rexulti (brexpiprazole) 2 mg tablets in a 30-count package. This firm fixed-price contract, awarded on January 14, 2026, with completion scheduled for January 15, 2026, represents a task order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery order carries no set-aside designation and will be fulfilled at...
- The Defense Logistics Agency awarded a $28,639.10 firm fixed-price delivery order to Amerisourcebergen Drug Corp (parent company Cencora, Inc.) on January 12, 2026, for the supply of Rexulti 1 mg tablets in quantities of 30 units. The contract, which concludes on January 13, 2026, was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a task order issued under Amerisourcebergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $74,612.17. This non-competitive delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 14, 2026, for the supply of Rexulti 2 mg tablets (30-count) with a ceiling value of $10,985.91. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The award is structured as a child contract under AmerisourceBergen's parent organization, Cencora, Inc., which holds a substantial Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,450.54 on November 6, 2025, for Rexulti 2 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing contract vehicle with DLA. The order is scheduled for completion by November 7, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $15,368.07 to AmerisourceBergen Drug Corp for Rexulti 1 mg tablets (30-count units) on August 18, 2025, with completion targeted for August 19, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Rexulti (brexpiprazole) is an atypical antipsychotic medication used in the treatment of psychiatric...
- SPE2DR25D2012Indefinite Delivery Contract
- SPE2DR25D2012-SPE2DR26F1BWNDelivery Order
The Defense Logistics Agency awarded a $5,259.62 delivery order to Amerisourcebergen Drug Corp (parent company Cencora, Inc.) on February 3, 2026, for the supply of Rexulti 2 mg tablets (30-count) with a completion date of February 4, 2026. This non-set-aside, firm fixed-price delivery order represents a competitively awarded task against a larger contract vehicle and will be performed at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is issued under Amerisourcebergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 billion through December 2026, which serves as a comprehensive pharmaceutical supply vehicle supporting military healthcare programs globally. The IDC covers a broad range of pharmaceutical products and medical supplies including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Rexulti (brexpiprazole) is an atypical antipsychotic medication used in the treatment of schizophrenia and major depressive disorder, consistent with Amerisourcebergen's role as a critical pharmaceutical distributor for federal military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.3k | 2/2/26 |